RADARS® System data have been utilized by manufacturers, regulatory agencies, and medical and public health officials to characterize and monitor prescription drug abuse, misuse, and diversion. The data have been presented at several United States (US) Food and Drug Administration (FDA) advisory committee meetings and scientific meetings as well as in reports to the FDA, new drug applications, labeling claims, post-market requirements, and Risk Evaluation and Mitigation Strategies (REMS) evaluation. Data may also be used for the development of interventions, to assess the impact of interventions (i.e. abuse deterrent formulations), and to monitor ever-changing market trends.
For more information about the RADARS® system, click here.